Physician profile
Peter J Gates
NPI 1154416782
$619.35
in general payments reported to CMS, 2019-2025
15 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $13.70 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $111.70 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.01 | 2025 | Jardiance |
| Abbvie INC. | $70.20 | 2024-2025 | |
| Lilly USA, LLC | $66.44 | 2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $63.58 | 2025 | Ozempic, Wegovy, Rybelsus |
| Baxter Healthcare | $32.94 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Lundbeck LLC | $32.39 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $24.96 | 2025 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $24.81 | 2025 | Gemtesa |
| Bausch Health US, LLC | $24.09 | 2025 | Wellbutrin, Aplenzin |
| Merck Sharp & Dohme LLC | $23.43 | 2025 | Capvaxive, Gardasil 9, M-M-R II |
| Otsuka America Pharmaceutical, INC. | $20.14 | 2025 | Rexulti |
| Pfizer INC. | $18.27 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $14.75 | 2025 | Zoryve |
| Echosens North America, INC. | $13.64 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Gates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.